Antibody–drug conjugates come of age in oncology
C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
Emerging new therapeutic antibody derivatives for cancer treatment
S Jin, Y Sun, X Liang, X Gu, J Ning, Y Xu… - Signal transduction and …, 2022 - nature.com
Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …
enhance natural immune system functions to suppress cancer cell activity and eliminate …
Development of therapeutic antibodies for the treatment of diseases
It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
Phage display derived monoclonal antibodies: from bench to bedside
MA Alfaleh, HO Alsaab, AB Mahmoud… - Frontiers in …, 2020 - frontiersin.org
Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …
biopharmaceutical products, and they continue to dominate the universe of …
Antibodies to watch in 2019
H Kaplon, JM Reichert - MAbs, 2019 - Taylor & Francis
For the past 10 years, the annual 'Antibodies to watch'articles have provided updates on key
events in the late-stage development of antibody therapeutics, such as first regulatory review …
events in the late-stage development of antibody therapeutics, such as first regulatory review …
CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial
NN Shah, SL Highfill, H Shalabi, B Yates… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with B-cell acute lymphoblastic leukemia who experience relapse after
or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting …
or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting …
Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia
E Tiacci, L De Carolis, E Simonetti… - … England Journal of …, 2021 - Mass Medical Soc
Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Abstract Background Targeting of MDSCs is a major clinical challenge in the era of
immunotherapy. Antibodies which deplete MDSCs in murine models can reactivate T cell …
immunotherapy. Antibodies which deplete MDSCs in murine models can reactivate T cell …
An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages
Antibodies as ideal therapeutic and diagnostic molecules are among the top-selling drugs
providing considerable efficacy in disease treatment, especially in cancer therapy …
providing considerable efficacy in disease treatment, especially in cancer therapy …
[HTML][HTML] Phage display derived peptides for Alzheimer's disease therapy and diagnosis
X Zhang, X Zhang, H Gao, G Qing - Theranostics, 2022 - ncbi.nlm.nih.gov
Alzheimer's disease (AD) is an incurable and fatal progressive neurodegenerative disorder
associated with memory and cognition impairment. AD is one of the top medical care …
associated with memory and cognition impairment. AD is one of the top medical care …